Navigation Links
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
Date:8/6/2009

products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales in excess of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signalling pathway drug technologies to seek to create new medicines for cancer indications. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signalling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at http://www.curis.com.

Curis Cautionary Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation the Company's statements regarding: the expected timing and amount of payments to be received by Curis under the license agreement with Debiopharm and the expected benefits of the agreement; Debiopharm's plans to seek approval for the commencement of a phase I clinical trial in Fall 2009; the estimated period in which Curis will have cash to meet its operating requirements and its assumptions about factors that may positively affect such period; expectations regarding the potential benefits of CUDC- 305; its ability to further progres
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
2. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
5. Japanese Cancer Association and Debiopharm Honour Japanese Research
6. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
7. Debiopharm and EPFL Establish an Oncology Chair
8. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
9. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
10. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
11. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... famous for a number of breakthroughs, which altered the ... a paper, which laid the foundation of computer science, ... He next played a pivotal role in the Second ... military codes, enabling the Allies to defeat the Nazis ... he turned his attention to artificial intelligence and proposed ...
(Date:7/31/2014)... 2014 According to a new ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... at USD 88.5 million in 2011, which is expected ... a CAGR of 53.8% from 2013 to 2023. ... http://www.transparencymarketresearch.com/quantum-dots.html Increasing demand for energy efficient ...
(Date:7/31/2014)... DUBLIN , July 31, 2014 ... the "Global Genomics Market 2014-2018" report to ... Genomics is the study of the genetic ... to be a strong basis for the discovery and ... of human diseases or health conditions. Genomics is supported ...
(Date:7/31/2014)... San Francisco, Calif. (PRWEB) July 31, 2014 ... provides newly diagnosed patients with an overview of the ... the management of drug side effects, as well as ... , “We’re grateful to Dr. Sandy Srinivas for organizing ... 25-year survivor of kidney cancer. “Sandy and her colleagues ...
Breaking Biology Technology:A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... Inc., a privately-,held, specialty pharmaceutical company, announced today ... financing, which included investors Domain Associates,Latterell Venture Partners ... committed to the development of prescription,products based on ... unmet,needs of patients and their caregivers. Meritage Pharma,s ...
... and existing antibiotics to create a broad offering of ... ... LONDON, June 16 Mpex Pharmaceuticals and,GlaxoSmithKline (GSK) today announced ... discovery, development and,commercialization of novel medicines for bacterial diseases. The,collaboration ...
... Medullary Thyroid Cancer Planned to Initiate This Summer, ... Inc. (Nasdaq: EXEL ) announced today that ... (FDA) have reached agreement on the phase 3,registration ... targeting,MET, RET, and VEGFR2, via the Special Protocol ...
Cached Biology Technology:Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing 2GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 2GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 3GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 4GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 5Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 4Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 5
(Date:7/31/2014)... Oren Tessler, Assistant Professor of Clinical Surgery at LSU ... part of a team of plastic and reconstructive surgeons ... to screen and select patients for a specific surgical ... who underwent this surgery to decompress the nerves that ... cosmetic eyelid surgery. The study, which confirms the benefit ...
(Date:7/31/2014)... Biometrics industry sees growth as ... companies turn towards digital currency: NXT-ID, Inc. (OTCBB: NXTD), ... (NASDAQ: AMZN ), Facebook Inc. (NASDAQ: ... ) and Microsoft Corporation (NASDAQ: MSFT) NXT-ID, Inc., ... m-commerce market, announces a video featuring its next generation ...
(Date:7/30/2014)... paving the way for a breakthrough that may ... exposed to poisonous chemicalsparticularly those in pesticides and ... current issue of the journal ChemBioChem ... compounds commonly used in pesticides and warfare agents. ... of Engineering Associate Professor of Chemical and Biological ...
Breaking Biology News(10 mins):Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6Engineering a protein to prevent brain damage from toxic agents 2
... 6, 2013  Daniel P. Linskey, superintendent-in-chief of the Boston ... Marathon Bombings" at the 2013 IEEE International Conference on Technologies ... Linskey,s talk will focus on the aftermath of the tragic ... department and federal enforcement agencies that ultimately led to the ...
... in the early 1990s, the protein STAT1 (Signal Transducer ... be central in passing signals across immune cells, ensuring ... from viruses or other pathogens. Animals without STAT1 are ... somehow involved in protection against malignant cells. The STAT1 ...
... To protect consumers, screening shellfish for fungal toxins is ... September) in the Society for Applied Microbiology (SfAM) journal, ... an area with contamination by strains of Penicillium ... will contain toxins at much higher levels that are ...
Cached Biology News:Boston Police Chief to Address Boston Marathon Bombings at IEEE Homeland Security Conference in Waltham, Mass., on 12 November 2Static killers? 2
Request Info...
supplied with 10x reaction buffer...
... ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: NADP ... of HK will phosphorylate 1 ... min at 25C at pH ... will oxidize 1 mol of ...
Request Info...
Biology Products: